Leuprorelin Acetate
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastases
Conditions
Metastases
Trial Timeline
Jul 1, 2011 → Sep 1, 2027
NCT ID
NCT01442246About Leuprorelin Acetate
Leuprorelin Acetate is a phase 3 stage product being developed by Astellas Pharma for Metastases. The current trial status is active. This product is registered under clinical trial identifier NCT01442246. Target conditions include Metastases.
What happened to similar drugs?
0 of 11 similar drugs in Metastases were approved
Approved (0) Terminated (0) Active (11)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01442246 | Phase 3 | Active |
| NCT00378690 | Phase 3 | Completed |
Competing Products
20 competing products in Metastases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2780301 | Eli Lilly | Phase 1 | 29 |
| Abemaciclib + Endocrine therapy | Eli Lilly | Phase 1/2 | 39 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 27 |
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 35 |
| Denosumab + Zoledronic Acid | Daiichi Sankyo | Phase 3 | 40 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 42 |
| ALIMTA + folic acid + multi-vitamins | Eli Lilly | Phase 1 | 29 |
| Merestinib | Eli Lilly | Phase 1 | 21 |
| LY2584702 + Erlotinib + Everolimus | Eli Lilly | Phase 1 | 21 |
| Veliparib + Placebo | AbbVie | Phase 2 | 35 |
| temozolomide | Merck | Phase 2 | 27 |
| Vorinostat | Merck | Phase 1 | 29 |
| Pembrolizumab | Merck | Phase 2 | 39 |
| EMD 525797 | Merck | Phase 1 | 29 |
| Temozolomide | Merck | Phase 2 | 35 |
| cabazitaxel + lapatinib | Novartis | Phase 2 | 27 |
| BKM120 + capecitabine + Trastuzumab | Novartis | Phase 2 | 35 |
| Zoledronic acid | Novartis | Phase 3 | 40 |
| zoledronic acid | Novartis | Phase 1 | 29 |
| capecitabine + lapatinib + trastuzumab | Novartis | Phase 3 | 40 |